Tango, Gilead partner to discover immune evasion cancer targets

Tango Therapeutics Inc. (Cambridge, Mass.) and Gilead Sciences Inc. (NASDAQ:GILD) will employ Tango's functional genome-based platform to discover tumor-intrinsic immune evasion targets. Gilead will have worldwide options to five targets under the deal.

Tango will receive $50 million up front and be eligible to receive about $1.7 billion in preclinical fees and milestones, plus low double-digit tiered royalties...